BUBENDORF, SWITZERLAND, October 20, 2025 – CIS BIOPHARMA AG, a company pioneering new cancer targets, announces that the company will present an abstract & poster about its lead ADC called CBO-001 at this year’s American Association for Cancer Research -AACR- NCI-EORTC- International Conference on Molecular Targets and Cancer Therapeutics.  

The AACR-NCI-EORTC will be held October 22-26, 2025, at the Boston Hynes Convention Center in Boston, Massachusetts. The poster highlights preclinical data on CBO-001, a proprietary antibody-drug conjugate (ADC) developed by CIS BIOPHARMA. “We are excited to share our preclinical data at this year’s AACR-NCI-EORTC meeting, demonstrating exceptional efficacy of our L1CAM ADC in several cancer indications, with outstanding results in small-cell lung cancer and ovarian cancer,” says Dominik Brücher, Ph.D., Chief Technology Officer of CIS BIOPHARMA AG.

“The superior pre-clinical efficacy of this emerging cancer target versus standard-of-care and other emerging targets such as B7H3 and DLL3 in SCLC, positions us in a unique competitive situation, also envisioning combination strategies with these. Our overall goal with CBO-001 is to develop therapeutic options with superior overall survival for patients with SCLC, OC and other L1CAM positive malignancies.”

About CIS BIOPHARMA AG

CIS BIOPHARMA is a privately owned, Basel-based oncology company that develops next-generation immuno-conjugates to address aggressive forms of tumors. The product pipeline includes antibody-drug conjugates, ADCs, and radioligand therapies, RLTs, selectively targeting tumor cells. CIS BIOPHARMA aims to help cancer patients live longer and better lives.